TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

Susan O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.